Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced receiving clinical trial approvals for its drug candidates SHR-1819, SHR-2002, and adebrelimab (SHR-1316). SHR-1819 is now cleared to enter Phase II clinical trials for chronic sinusitis with nasal polyps, and SHR-2002 will proceed to a Phase I clinical study in advanced malignant tumors, used both as a monotherapy and in combination with chemotherapy alongside adebrelimab.
SHR-1819: Targeting Chronic Sinusitis with Nasal Polyps
SHR-1819, which can block the interleukin pathway, is designed to inhibit the conduction of downstream inflammatory signals, ultimately improving the inflammatory state and controlling disease progression. A comparable product in the market, as cited by Hengrui, is Sanofi’s Dupixent (dupilumab), used for treating atopic dermatitis.
Adebrelimab: A PD-L1 Monoclonal Antibody for Lung Cancer
Adebrelimab, a programmed death-ligand 1 (PD-L1) monoclonal antibody (mAb), obtained market approval in China in March 2023 for the treatment of first-line extensive stage small-cell lung cancer (ES-SCLC) in combination with chemotherapy.
SHR-2002: A Pioneering Bispecific Antibody in Clinical Development
SHR-2002 is a bispecific antibody (BsAb) that is noted as the first of its kind to reach clinical stages globally. This innovative drug candidate is set to undergo further investigation in the treatment of advanced malignant tumors.-Fineline Info & Tech
